{"id":10922,"date":"2026-09-20T08:42:42","date_gmt":"2026-09-20T08:42:42","guid":{"rendered":"https:\/\/europepharmacy.eu\/?post_type=product&#038;p=10922"},"modified":"2026-09-20T08:42:43","modified_gmt":"2026-09-20T08:42:43","slug":"inbec-tablet-abacavir-dolutegravir-lamivudine","status":"publish","type":"product","link":"https:\/\/europepharmacy.eu\/nl\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/","title":{"rendered":"Inbec Tablet Abacavir Dolutegravir Lamivudine"},"content":{"rendered":"<p data-path-to-node=\"11\">Inbec (manufactured by Emcure Pharmaceuticals) provides a complete, co-formulated triple-drug regimen in a single solid-dose oral tablet. Designed to streamline chronic antiretroviral therapy (cART), it reduces pill burden and simplifies adherence schedules by eliminating the need for co-administered companion antiretrovirals. Integrating dolutegravir with a dual-NRTI backbone of abacavir and lamivudine, Inbec targets two distinct phases of the retroviral life cycle, promoting rapid reduction of viral load to undetectable levels while preserving <span class=\"math-inline\" data-math=\"\\text{CD4}^+\" data-index-in-node=\"552\">$\\text{CD4}^+$<\/span> T-cell populations.<\/p>\n<p data-path-to-node=\"12\"><b data-path-to-node=\"12\" data-index-in-node=\"0\">Active Pharmaceutical Constituents &amp; Formulation<\/b><\/p>\n<ul data-path-to-node=\"13\">\n<li>\n<p data-path-to-node=\"13,0,0\"><b data-path-to-node=\"13,0,0\" data-index-in-node=\"0\">Abacavir Sulfate:<\/b> 600 mg (equivalent to 702 mg abacavir sulfate) \u2014 A carbocyclic synthetic purine nucleoside analogue.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"13,1,0\"><b data-path-to-node=\"13,1,0\" data-index-in-node=\"0\">Dolutegravir Sodium:<\/b> 50 mg (equivalent to 52.6 mg dolutegravir sodium) \u2014 A second-generation integrase strand transfer inhibitor (INSTI).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"13,2,0\"><b data-path-to-node=\"13,2,0\" data-index-in-node=\"0\">Lamivudine (3TC):<\/b> 300 mg \u2014 A synthetic cytosine nucleoside analogue.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"13,3,0\"><b data-path-to-node=\"13,3,0\" data-index-in-node=\"0\">Dosage Form:<\/b> Film-coated, biconvex, capsule-shaped oral tablets manufactured under rigorous current Good Manufacturing Practices (cGMP) for bioequivalence to reference innovator formulations.<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"14\"><b data-path-to-node=\"14\" data-index-in-node=\"0\">Pharmacodynamics &amp; Triple-Target Mechanism of Action<\/b><\/p>\n<ul data-path-to-node=\"15\">\n<li>\n<p data-path-to-node=\"15,0,0\"><b data-path-to-node=\"15,0,0\" data-index-in-node=\"0\">Integration Blockade (Dolutegravir):<\/b> Selectively inhibits retroviral integrase by chelating two essential divalent magnesium ions (<span class=\"math-inline\" data-math=\"\\text{Mg}^{2+}\" data-index-in-node=\"131\">$\\text{Mg}^{2+}$<\/span>) positioned within the catalytic triad (DDE motif) of the enzyme&#8217;s active core. This halts the essential strand-transfer step, preventing the covalent insertion of linearized viral pre-integration cDNA into host chromosomal DNA. The slow dissociation off-rate of dolutegravir provides a high genetic barrier against viral mutational resistance.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"15,1,0\"><b data-path-to-node=\"15,1,0\" data-index-in-node=\"0\">Dual Reverse Transcriptase Inhibition &amp; Chain Termination (Abacavir &amp; Lamivudine):<\/b><\/p>\n<ul data-path-to-node=\"15,1,1\">\n<li>\n<p data-path-to-node=\"15,1,1,0,0\"><i data-path-to-node=\"15,1,1,0,0\" data-index-in-node=\"0\">Intracellular Phosphorylation:<\/i> Following passive cellular uptake, abacavir undergoes multi-step enzymatic biotransformation to its active metabolite, carbovir 5&#8242;-triphosphate (<span class=\"math-inline\" data-math=\"\\text{CBV-TP}\" data-index-in-node=\"176\">$\\text{CBV-TP}$<\/span>). Concurrently, lamivudine is phosphorylated by intracellular deoxycytidine kinases to lamivudine 5&#8242;-triphosphate (<span class=\"math-inline\" data-math=\"\\text{3TC-TP}\" data-index-in-node=\"305\">$\\text{3TC-TP}$<\/span>).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"15,1,1,1,0\"><i data-path-to-node=\"15,1,1,1,0\" data-index-in-node=\"0\">Competitive Enzyme Inhibition:<\/i> Both triphosphates structurally mimic natural endogenous nucleotides (deoxyguanosine triphosphate and deoxycytidine triphosphate, respectively), competitively inhibiting HIV-1 reverse transcriptase.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"15,1,1,2,0\"><i data-path-to-node=\"15,1,1,2,0\" data-index-in-node=\"0\">Premature Chain Termination:<\/i> Because both molecules lack the essential 3&#8242;-hydroxyl (<span class=\"math-inline\" data-math=\"3'\\text{-OH}\" data-index-in-node=\"84\">$3&#8217;\\text{-OH}$<\/span>) group required for phosphodiester bond propagation, their incorporation into nascent viral cDNA causes immediate, irreversible termination of viral DNA synthesis.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"16\"><b data-path-to-node=\"16\" data-index-in-node=\"0\">Pharmacokinetics &amp; Biotransformation<\/b><\/p>\n<ul data-path-to-node=\"17\">\n<li>\n<p data-path-to-node=\"17,0,0\"><b data-path-to-node=\"17,0,0\" data-index-in-node=\"0\">Absorption &amp; Food Effect:<\/b> Rapidly and well-absorbed following oral ingestion. Peak plasma concentrations (<span class=\"math-inline\" data-math=\"C_{\\max}\" data-index-in-node=\"106\">$C_{\\max}$<\/span>) are reached within 1.5 to 2.5 hours for abacavir, 2 to 3 hours for dolutegravir, and 1 to 1.5 hours for lamivudine. Inbec can be taken with or without food, as systemic exposure (<span class=\"math-inline\" data-math=\"\\text{AUC}\" data-index-in-node=\"295\">$\\text{AUC}$<\/span>) is not clinically altered by meals.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,1,0\"><b data-path-to-node=\"17,1,0\" data-index-in-node=\"0\">Metabolism &amp; Elimination:<\/b><\/p>\n<ul data-path-to-node=\"17,1,1\">\n<li>\n<p data-path-to-node=\"17,1,1,0,0\"><i data-path-to-node=\"17,1,1,0,0\" data-index-in-node=\"0\">Dolutegravir:<\/i> Cleared hepatically via UDP-glucuronosyltransferase 1A1 (<span class=\"math-inline\" data-math=\"\\text{UGT1A1}\" data-index-in-node=\"71\">$\\text{UGT1A1}$<\/span>) with minor cytochrome P450 3A4 (<span class=\"math-inline\" data-math=\"\\text{CYP3A4}\" data-index-in-node=\"118\">$\\text{CYP3A4}$<\/span>) clearance. Displays an elimination half-life of ~14 hours.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,1,1,1,0\"><i data-path-to-node=\"17,1,1,1,0\" data-index-in-node=\"0\">Abacavir:<\/i> Extensively metabolized via alcohol dehydrogenase (<span class=\"math-inline\" data-math=\"\\text{ADH}\" data-index-in-node=\"61\">$\\text{ADH}$<\/span>) and <span class=\"math-inline\" data-math=\"\\text{UGT}\" data-index-in-node=\"77\">$\\text{UGT}$<\/span> glucuronidation, avoiding primary cytochrome P450 pathways. Plasma half-life is 1.5 to 2.0 hours, but intracellular <span class=\"math-inline\" data-math=\"\\text{CBV-TP}\" data-index-in-node=\"204\">$\\text{CBV-TP}$<\/span> exhibits an extended half-life exceeding 20 hours.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,1,1,2,0\"><i data-path-to-node=\"17,1,1,2,0\" data-index-in-node=\"0\">Lamivudine:<\/i> Excreted predominantly unchanged into urine via active organic cationic secretion and glomerular filtration, with a plasma half-life of 5 to 7 hours and an intracellular <span class=\"math-inline\" data-math=\"\\text{3TC-TP}\" data-index-in-node=\"182\">$\\text{3TC-TP}$<\/span> half-life of 16 to 19 hours.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"18\"><b data-path-to-node=\"18\" data-index-in-node=\"0\">Critical Pharmacogenomic Warning: HLA-B*5701 Allele &amp; Hypersensitivity<\/b><\/p>\n<ul data-path-to-node=\"19\">\n<li>\n<p data-path-to-node=\"19,0,0\"><b data-path-to-node=\"19,0,0\" data-index-in-node=\"0\">Mandatory Screening Requirement:<\/b> Prior to initiating Inbec therapy, all prospective patients <b data-path-to-node=\"19,0,0\" data-index-in-node=\"93\">must<\/b> undergo genetic screening for the human leukocyte antigen allele <span class=\"math-inline\" data-math=\"\\text{HLA-B*5701}\" data-index-in-node=\"163\">$\\text{HLA-B*5701}$<\/span>.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"19,1,0\"><b data-path-to-node=\"19,1,0\" data-index-in-node=\"0\">Abacavir Hypersensitivity Reaction (AHR):<\/b> The carriage of <span class=\"math-inline\" data-math=\"\\text{HLA-B*5701}\" data-index-in-node=\"58\">$\\text{HLA-B*5701}$<\/span> carries a severe risk of triggering an immune-mediated hypersensitivity cascade. Abacavir binds directly within the antigen-presenting groove of the <span class=\"math-inline\" data-math=\"\\text{HLA-B*5701}\" data-index-in-node=\"225\">$\\text{HLA-B*5701}$<\/span> molecule, inducing massive self-reactive <span class=\"math-inline\" data-math=\"\\text{CD8}^+\" data-index-in-node=\"284\">$\\text{CD8}^+$<\/span> T-cell activation. Symptoms typically emerge within the first six weeks of therapy and involve at least two of the following:<\/p>\n<ul data-path-to-node=\"19,1,1\">\n<li>\n<p data-path-to-node=\"19,1,1,0,0\">High fever, constitutional malaise, and fatigue.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"19,1,1,1,0\">Maculopapular, confluent, or generalized cutaneous rash.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"19,1,1,2,0\">Severe nausea, persistent vomiting, diarrhea, or abdominal pain.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"19,1,1,3,0\">Dyspnea, cough, or pharyngitis.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p data-path-to-node=\"19,2,0\"><b data-path-to-node=\"19,2,0\" data-index-in-node=\"0\">Permanent Discontinuation:<\/b> If AHR is suspected, Inbec must be discontinued immediately and permanently. <b data-path-to-node=\"19,2,0\" data-index-in-node=\"104\">Rechallenging a patient with any abacavir-containing formulation is strictly contraindicated<\/b>, as it can provoke immediate hemodynamic collapse, multi-organ failure, and death within hours.<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"20\"><b data-path-to-node=\"20\" data-index-in-node=\"0\">Clinical Indications &amp; Prescribing Restrictions<\/b><\/p>\n<ul data-path-to-node=\"21\">\n<li>\n<p data-path-to-node=\"21,0,0\"><b data-path-to-node=\"21,0,0\" data-index-in-node=\"0\">Indications:<\/b> Indicated as a complete standalone regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg who are confirmed <span class=\"math-inline\" data-math=\"\\text{HLA-B*5701}\" data-index-in-node=\"168\">$\\text{HLA-B*5701}$<\/span>-negative and have no documented phenotypic or genotypic resistance to the INSTI or NRTI classes.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"21,1,0\"><b data-path-to-node=\"21,1,0\" data-index-in-node=\"0\">Renal Function Threshold:<\/b> Because Inbec is a fixed-dose combination that cannot be individually adjusted, it is <b data-path-to-node=\"21,1,0\" data-index-in-node=\"112\">not recommended<\/b> for patients with moderate-to-severe renal impairment (creatinine clearance <span class=\"math-inline\" data-math=\"\\text{CrCl} &lt; 50\\text{ mL\/min}\" data-index-in-node=\"204\">$\\text{CrCl} &lt; 50\\text{ mL\/min}$<\/span>), as lamivudine requires dose interval titration below this clearance rate.<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"22\"><b data-path-to-node=\"22\" data-index-in-node=\"0\">Key Drug-Drug Interactions &amp; Safety Warnings<\/b><\/p>\n<ul data-path-to-node=\"23\">\n<li>\n<p data-path-to-node=\"23,0,0\"><b data-path-to-node=\"23,0,0\" data-index-in-node=\"0\">Polyvalent Metal Cation Chelation:<\/b> Dolutegravir binds readily to polyvalent metal cations (<span class=\"math-inline\" data-math=\"\\text{Mg}^{2+}, \\text{Al}^{3+}, \\text{Ca}^{2+}, \\text{Fe}^{2+}\" data-index-in-node=\"91\">$\\text{Mg}^{2+}, \\text{Al}^{3+}, \\text{Ca}^{2+}, \\text{Fe}^{2+}$<\/span>). Inbec must be administered at least 2 hours before or 6 hours after taking cation-containing antacids, laxatives, sucralfate, or oral mineral\/iron supplements.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"23,1,0\"><b data-path-to-node=\"23,1,0\" data-index-in-node=\"0\">Enzyme Inducers (e.g., Rifampicin):<\/b> Co-administration with potent metabolic inducers markedly accelerates dolutegravir clearance. Concomitant use with rifampicin requires supplemental single-entity dolutegravir (50 mg taken 12 hours apart from the FDC tablet), which must be coordinated under specialized clinical supervision.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"23,2,0\"><b data-path-to-node=\"23,2,0\" data-index-in-node=\"0\">Metformin Interactions:<\/b> Dolutegravir inhibits renal transporters <span class=\"math-inline\" data-math=\"\\text{OCT2}\" data-index-in-node=\"65\">$\\text{OCT2}$<\/span> en <span class=\"math-inline\" data-math=\"\\text{MATE1}\" data-index-in-node=\"81\">$\\text{MATE1}$<\/span>, elevating circulating metformin plasma concentrations. Close blood glucose monitoring and potential metformin dosage reductions are recommended.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"23,3,0\"><b data-path-to-node=\"23,3,0\" data-index-in-node=\"0\">Exacerbation of Hepatitis B (HBV):<\/b> Lamivudine possesses antiviral activity against HBV. Discontinuation of Inbec in individuals co-infected with HIV-1 and HBV can precipitate acute, severe hepatic flares. Periodic liver function monitoring is required if the drug is stopped.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"23,4,0\"><b data-path-to-node=\"23,4,0\" data-index-in-node=\"0\">Lactic Acidosis &amp; Severe Hepatomegaly with Steatosis:<\/b> Class-wide warning for nucleoside analogues associated with mitochondrial polymerase-<span class=\"math-inline\" data-math=\"\\gamma\" data-index-in-node=\"139\">$\\gamma$<\/span> toxicity, manifesting as metabolic lactic acidosis, tachypnea, and hepatic steatosis.<\/p>\n<\/li>\n<\/ul>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div>","protected":false},"excerpt":{"rendered":"<p>Inbec is a prescription-only, fixed-dose combination (FDC) antiretroviral tablet containing abacavir sulfate (600 mg), dolutegravir sodium (50 mg), and lamivudine (300 mg). Formulated as a generic bioequivalent alternative to Triumeq\u00ae, it provides a complete once-daily single-tablet regimen (STR) for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents weighing at least 40 kg. By combining a second-generation integrase strand transfer inhibitor (INSTI) with two nucleoside reverse transcriptase inhibitors (NRTIs), Inbec suppresses viral replication with a high genetic barrier to resistance. Mandatory pharmacogenomic screening for the <span class=\"math-inline\" data-math=\"\\text{HLA-B*5701}\" data-index-in-node=\"685\">$\\text{HLA-B*5701}$<\/span> allele is required prior to initiation. Dispensed strictly by medical prescription.<\/p>","protected":false},"featured_media":10926,"comment_status":"open","ping_status":"closed","template":"","meta":{"postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""}},"product_brand":[],"product_cat":[506,1073],"product_tag":[1145,1150,1092,1146,1078,1149,1144,1148,1105,1147],"class_list":["post-10922","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-viral","product_cat-hivaid","product_tag-abacavir-dolutegravir-lamivudine","product_tag-emcure-inbec","product_tag-fixed-dose-combination-hiv","product_tag-generic-triumeq","product_tag-hiv-1-antiretroviral","product_tag-hla-b5701-tested","product_tag-inbec-tablet","product_tag-insti-dual-nrti","product_tag-prescription-hiv-medication","product_tag-single-tablet-regimen","instock","sale","shipping-taxable","purchasable","product-type-simple"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Inbec Tablet Abacavir Dolutegravir Lamivudine<\/title>\n<meta name=\"description\" content=\"Inbec (abacavir, dolutegravir, lamivudine) tablets: Once-daily fixed-dose regimen for HIV-1. Multi-target MoA, pharmacokinetics, and HLA-B*5701 boxed warning.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/europepharmacy.eu\/nl\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inbec Tablet Abacavir Dolutegravir Lamivudine\" \/>\n<meta property=\"og:description\" content=\"Inbec is a prescription-only, fixed-dose combination (FDC) antiretroviral tablet containing abacavir sulfate (600 mg), dolutegravir sodium (50 mg), and lamivudine (300 mg). Formulated as a generic bioequivalent alternative to Triumeq\u00ae, it provides a complete once-daily single-tablet regimen (STR) for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents weighing at least 40 kg. By combining a second-generation integrase strand transfer inhibitor (INSTI) with two nucleoside reverse transcriptase inhibitors (NRTIs), Inbec suppresses viral replication with a high genetic barrier to resistance. Mandatory pharmacogenomic screening for the $text{HLA-B*5701}$ allele is required prior to initiation. Dispensed strictly by medical prescription.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/europepharmacy.eu\/nl\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/\" \/>\n<meta property=\"og:site_name\" content=\"European Pharmacy\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-20T08:42:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/inbec-500x500-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/inbec-tablet-abacavir-dolutegravir-lamivudine\\\/\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/inbec-tablet-abacavir-dolutegravir-lamivudine\\\/\",\"name\":\"Inbec Tablet Abacavir Dolutegravir Lamivudine\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/inbec-tablet-abacavir-dolutegravir-lamivudine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/inbec-tablet-abacavir-dolutegravir-lamivudine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/inbec-500x500-1.webp\",\"datePublished\":\"2026-09-20T08:42:42+00:00\",\"dateModified\":\"2026-09-20T08:42:43+00:00\",\"description\":\"Inbec (abacavir, dolutegravir, lamivudine) tablets: Once-daily fixed-dose regimen for HIV-1. Multi-target MoA, pharmacokinetics, and HLA-B*5701 boxed warning.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/inbec-tablet-abacavir-dolutegravir-lamivudine\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/inbec-tablet-abacavir-dolutegravir-lamivudine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/inbec-tablet-abacavir-dolutegravir-lamivudine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/inbec-500x500-1.webp\",\"contentUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/inbec-500x500-1.webp\",\"width\":500,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/inbec-tablet-abacavir-dolutegravir-lamivudine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/europepharmacy.eu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shop\",\"item\":\"https:\\\/\\\/europepharmacy.eu\\\/shop\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Inbec Tablet Abacavir Dolutegravir Lamivudine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#website\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/\",\"name\":\"European Pharmacy\",\"description\":\"Order Medication &amp; Pills Online\",\"publisher\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/europepharmacy.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#organization\",\"name\":\"European Pharmacy\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg\",\"contentUrl\":\"https:\\\/\\\/europepharmacy.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg\",\"width\":1254,\"height\":1254,\"caption\":\"European Pharmacy\"},\"image\":{\"@id\":\"https:\\\/\\\/europepharmacy.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Inbec Tablet Abacavir Dolutegravir Lamivudine","description":"Inbec (abacavir, dolutegravir, lamivudine) tablets: Once-daily fixed-dose regimen for HIV-1. Multi-target MoA, pharmacokinetics, and HLA-B*5701 boxed warning.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/europepharmacy.eu\/nl\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/","og_locale":"nl_NL","og_type":"article","og_title":"Inbec Tablet Abacavir Dolutegravir Lamivudine","og_description":"Inbec is a prescription-only, fixed-dose combination (FDC) antiretroviral tablet containing abacavir sulfate (600 mg), dolutegravir sodium (50 mg), and lamivudine (300 mg). Formulated as a generic bioequivalent alternative to Triumeq\u00ae, it provides a complete once-daily single-tablet regimen (STR) for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents weighing at least 40 kg. By combining a second-generation integrase strand transfer inhibitor (INSTI) with two nucleoside reverse transcriptase inhibitors (NRTIs), Inbec suppresses viral replication with a high genetic barrier to resistance. Mandatory pharmacogenomic screening for the $text{HLA-B*5701}$ allele is required prior to initiation. Dispensed strictly by medical prescription.","og_url":"https:\/\/europepharmacy.eu\/nl\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/","og_site_name":"European Pharmacy","article_modified_time":"2026-09-20T08:42:43+00:00","og_image":[{"width":500,"height":500,"url":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/inbec-500x500-1.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Geschatte leestijd":"4 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/europepharmacy.eu\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/","url":"https:\/\/europepharmacy.eu\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/","name":"Inbec Tablet Abacavir Dolutegravir Lamivudine","isPartOf":{"@id":"https:\/\/europepharmacy.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/europepharmacy.eu\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/#primaryimage"},"image":{"@id":"https:\/\/europepharmacy.eu\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/#primaryimage"},"thumbnailUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/inbec-500x500-1.webp","datePublished":"2026-09-20T08:42:42+00:00","dateModified":"2026-09-20T08:42:43+00:00","description":"Inbec (abacavir, dolutegravir, lamivudine) tablets: Once-daily fixed-dose regimen for HIV-1. Multi-target MoA, pharmacokinetics, and HLA-B*5701 boxed warning.","breadcrumb":{"@id":"https:\/\/europepharmacy.eu\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/europepharmacy.eu\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/europepharmacy.eu\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/#primaryimage","url":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/inbec-500x500-1.webp","contentUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/inbec-500x500-1.webp","width":500,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/europepharmacy.eu\/shop\/inbec-tablet-abacavir-dolutegravir-lamivudine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/europepharmacy.eu\/"},{"@type":"ListItem","position":2,"name":"Shop","item":"https:\/\/europepharmacy.eu\/shop\/"},{"@type":"ListItem","position":3,"name":"Inbec Tablet Abacavir Dolutegravir Lamivudine"}]},{"@type":"WebSite","@id":"https:\/\/europepharmacy.eu\/#website","url":"https:\/\/europepharmacy.eu\/","name":"European Pharmacy","description":"Order Medication &amp; Pills Online","publisher":{"@id":"https:\/\/europepharmacy.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/europepharmacy.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/europepharmacy.eu\/#organization","name":"European Pharmacy","url":"https:\/\/europepharmacy.eu\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/europepharmacy.eu\/#\/schema\/logo\/image\/","url":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg","contentUrl":"https:\/\/europepharmacy.eu\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-07-at-18.41.53.jpeg","width":1254,"height":1254,"caption":"European Pharmacy"},"image":{"@id":"https:\/\/europepharmacy.eu\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/product\/10922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/comments?post=10922"}],"version-history":[{"count":1,"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/product\/10922\/revisions"}],"predecessor-version":[{"id":10927,"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/product\/10922\/revisions\/10927"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/media\/10926"}],"wp:attachment":[{"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/media?parent=10922"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/product_brand?post=10922"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/product_cat?post=10922"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/europepharmacy.eu\/nl\/wp-json\/wp\/v2\/product_tag?post=10922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}